Ainos, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Ainos, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

Ainos, Inc. (AIMDW) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Ainos, Inc. filed a 10-Q report for the period ending March 31, 2024. The company's fiscal year ends on December 31st. Ainos, Inc. is incorporated in Texas. The company's SIC code is 2834 (Pharmaceutical Preparations). The filing was made on May 13, 2024.

Why It Matters

For investors and stakeholders tracking Ainos, Inc., this filing contains several important signals. This filing provides an update on Ainos, Inc.'s financial performance and operational status for the first quarter of 2024. Investors and stakeholders can use this report to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: low — Ainos, Inc. shows low risk based on this filing. The filing is a standard 10-Q report with no immediate red flags, indicating routine disclosure.

Analyst Insight

Review the detailed financial statements and management discussion within the 10-Q to understand Ainos, Inc.'s performance and outlook.

Key Numbers

• 2024-03-31 — Period of Report (Conformed period of report)
• 2024-05-13 — Filed As Of Date (Filed as of date)
• 0001014763 — Central Index Key (Central Index Key for Ainos, Inc.)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
• 751974352 — IRS Number (IRS Number for Ainos, Inc.)
• TX — State of Incorporation (State of incorporation)
• 1231 — Fiscal Year End (Fiscal year end)
• 001-41461 — SEC File Number (SEC file number)

Key Players & Entities

• Ainos, Inc. (company) — Filer name
• AIMD (company) — Ticker symbol
• 2024-03-31 (date) — Period of report
• 2024-05-13 (date) — Filing date
• 2834 (industry) — Standard Industrial Classification
• TX (location) — State of incorporation
• San Diego (location) — Business address city
• 858-869-2986 (phone) — Business phone

FAQ

Industry Context

Ainos, Inc. operates in the Pharmaceutical Preparations industry, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) detailing financial performance and business operations.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and net income for Q1 2024.
2. Review any disclosures regarding business operations, risks, and future outlook.
3. Compare current quarter performance to previous periods if historical data is available in the filing.

Key Dates

• 2024-03-31: Quarter End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update on the company's status since the last annual report.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar
• $1.00 — urther, to comply with Nasdaq's minimum $1.00 per share continued listing rules, the

Filing Documents

• form10-q.htm (10-Q) — 620KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-018885.txt (&nbsp;) — 3791KB
• aimd-20240331.xsd (EX-101.SCH) — 33KB
• aimd-20240331_cal.xml (EX-101.CAL) — 46KB
• aimd-20240331_def.xml (EX-101.DEF) — 157KB
• aimd-20240331_lab.xml (EX-101.LAB) — 268KB
• aimd-20240331_pre.xml (EX-101.PRE) — 222KB
• form10-q_htm.xml (XML) — 421KB

Financial Statements

Financial Statements 3 Condensed Balance Sheets– March 31, 2024 and December 31, 2023 (unaudited) 3 Condensed Statements of Operations – Three Months Ended March 31, 2024 and 2023 (unaudited) 4 Condensed Statements of Comprehensive Loss – Three Months Ended March 31, 2024 and 2023 (unaudited) 5 Condensed Statements of Stockholders' Equity– Three Months Ended March 31, 2024 and 2023 (unaudited) 6 Condensed Statements of Cash Flows – Three Months Ended March 31, 2024 and 2023 (unaudited) 7 Notes to Condensed Financial Statements (unaudited) 8 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 ITEM 4.

Controls and Procedures

Controls and Procedures 20 PART II: OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 21 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 21 ITEM 3. Defaults Upon Senior Securities 21 ITEM 4. Mine Safety Disclosures 21 ITEM 5. Other Information 22 ITEM 6. Exhibits 22

Signatures

Signatures 23 2 PART I - FINANCIAL INFORMATION ITEM 1. Financial Statements Ainos, Inc. Condensed Balance Sheets (Unaudited) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 1,030,899 $ 1,885,628 Accounts receivable 4,172 455 Inventory, net 169,655 167,593 Other current assets 304,608 419,521 Total current assets 1,509,334 2,473,197 Intangible assets, net 27,155,594 28,283,208 Property and equipment, net 768,665 876,572 Other assets 320,867 208,827 Total assets $ 29,754,460 $ 31,841,804 Liabilities and Stockholders' Equity Current liabilities: Contract liabilities $ 108,000 $ 112,555 Convertible notes payable, (including amounts of related party of $ 2,000,000 and nil as of March 31, 2024 and December 31, 2023 respectively) 3,000,000 - Convertible notes payable 3,000,000 - Other notes payable, related party 312,000 42,000 Accrued expenses and others current liabilities 1,285,973 1,182,283 Total current liabilities 4,705,973 1,336,838 Senior secured convertible notes measured at fair value 2,369,694 2,651,556 Convertible notes payable - noncurrent (including amounts of related party of nil and $ 2,000,000 as of March 31,2024 and December 31, 2023, respectively) - 3,000,000 Convertible notes payable - 3,000,000 Other notes payable, related party - noncurrent - 270,000 Other long-term liabilities - 135,829 Total liabilities 7,075,667 7,394,223 Commitments and contingencies - - Stockholders' equity: Preferred stock, $ 0.01 par value; 50,000,000 shares authorized; none issued and outstanding - - Common stock, $ 0.01 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, 6,144,506 and 4,677,787 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 61,445 46,778 Common stock to be issued, 270 shares and 162,337 shares as of March 31, 2024 and December

View Full Filing

View this 10-Q filing on SEC EDGAR